With its headquarters in Cambridge, Abcam was admitted to AIM in 2005 and has delivered handsomely for shareholders. The Group is a true global leader in the supply of life science research tools, with a wide range of products and expert technical support, enabling scientists to analyse living cells at the molecular level and improving the understanding of health and disease.
In the 6 months to 31st December product revenue increased to £62.7m (H1 2014: £56.8m), representing growth of 16.7% on a constant currency basis and 10.4% on a reported basis.
Total revenue increased to £66.7m (H1 2014: £61.9m), representing growth of 13.8% on a constant currency basis and 7.7% on a reported basis
Gross margins fell marginally to 70.4% (H1 2014: 70.9%), reflecting some currency headwinds in the period but the adjusted operating margin was still a whopping 35.4% (H1 2014: 36.8%), with reported operating margin 32.8% (H1 2014: 34.1%). EBITDA was £25.8m, representing growth of 5.8% over H1…
Register to continue reading this article.
Already a member? Login
For access to the top news and insights from the investment worldREGISTER FREE TODAY